Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo

Authors: Seung Joon Lee, Candice Krauthauser, Victoria Maduskuie, Paul T Fawcett, James M Olson, Sigrid A Rajasekaran

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Medulloblastoma is the most common brain tumor in children, and its prognosis is worse than for many other common pediatric cancers. Survivors undergoing treatment suffer from serious therapy-related side effects. Thus, it is imperative to identify safer, effective treatments for medulloblastoma. In this study we evaluated the anti-cancer potential of curcumin in medulloblastoma by testing its ability to induce apoptosis and inhibit tumor growth in vitro and in vivo using established medulloblastoma models.

Methods

Using cultured medulloblastoma cells, tumor xenografts, and the Smo/Smo transgenic medulloblastoma mouse model, the antitumor effects of curcumin were tested in vitro and in vivo.

Results

Curcumin induced apoptosis and cell cycle arrest at the G2/M phase in medulloblastoma cells. These effects were accompanied by reduced histone deacetylase (HDAC) 4 expression and activity and increased tubulin acetylation, ultimately leading to mitotic catastrophe. In in vivo medulloblastoma xenografts, curcumin reduced tumor growth and significantly increased survival in the Smo/Smo transgenic medulloblastoma mouse model.

Conclusions

The in vitro and in vivo data suggest that curcumin has the potential to be developed as a therapeutic agent for medulloblastoma.
Appendix
Available only for authorised users
Literature
1.
2.
Gilbertson RJ, Ellison DW: The origins of medulloblastoma subtypes. Annu Rev Pathol. 2008, 3: 341-365. 10.1146/annurev.pathmechdis.3.121806.151518.CrossRefPubMed
3.
Fossati P, Ricardi U, Orecchia R: Pediatric medulloblastoma: Toxicity of current treatment and potential role of protontherapy. Cancer Treatment Reviews. 2009, 35 (1): 79-96. 10.1016/j.ctrv.2008.09.002.CrossRefPubMed
4.
Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, Huillard E, Sun T, Ligon AH, Qian Y, et al: Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell. 2008, 14 (2): 123-134. 10.1016/j.ccr.2008.07.005.CrossRefPubMedPubMedCentral
5.
Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, et al: Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell. 2004, 6 (3): 229-240. 10.1016/j.ccr.2004.08.019.CrossRefPubMed
6.
Kimura H, Ng JMY, Curran T: Transient Inhibition of the Hedgehog Pathway in Young Mice Causes Permanent Defects in Bone Structure. Cancer Cell. 2008, 13 (3): 249-260. 10.1016/j.ccr.2008.01.027.CrossRefPubMed
7.
Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB: Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008, 267 (1): 133-164. 10.1016/j.canlet.2008.03.025.CrossRefPubMed
8.
Kunnumakkara AB, Anand P, Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008, 269 (2): 199-225. 10.1016/j.canlet.2008.03.009.CrossRefPubMed
9.
Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001, 21 (21): 8370-8377.PubMed
10.
Perry MC, Demeule M, Regina A, Moumdjian R, Beliveau R: Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol Nutr Food Res. 2010, 54 (8): 1192-201.PubMed
11.
Purkayastha S, Berliner A, Fernando SS, Ranasinghe B, Ray I, Tariq H, Banerjee P: Curcumin Blocks Brain Tumor Formation. Brain Res. 2009
12.
Deeken JF, Loscher W: The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007, 13 (6): 1663-1674. 10.1158/1078-0432.CCR-06-2854.CrossRefPubMed
13.
Zlokovic BV: The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008, 57 (2): 178-201. 10.1016/j.neuron.2008.01.003.CrossRefPubMed
14.
Fruhwald MC, Witt O: The epigenetics of cancer in children. Klin Padiatr. 2008, 220 (6): 333-341. 10.1055/s-0028-1086026.CrossRefPubMed
15.
Iacobuzio-Donahue CA: Epigenetic Changes in Cancer. Annual Review of Pathology: Mechanisms of Disease. 2009, 4 (1): 229-249. 10.1146/annurev.pathol.3.121806.151442.CrossRef
16.
Glozak MA, Sengupta N, Zhang X, Seto E: Acetylation and deacetylation of non-histone proteins. Gene. 2005, 363: 15-23. 10.1016/j.gene.2005.09.010.CrossRefPubMed
17.
Spange S, Wagner T, Heinzel T, Kramer OH: Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol. 2009, 41 (1): 185-198. 10.1016/j.biocel.2008.08.027.CrossRefPubMed
18.
Haberland M, Montgomery RL, Olson EN: The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009, 10 (1): 32-42. 10.1038/nrg2485.CrossRefPubMedPubMedCentral
19.
Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006, 5 (9): 769-784. 10.1038/nrd2133.CrossRefPubMed
20.
Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC: CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS*. Annual Review of Pharmacology and Toxicology. 2005, 45 (1): 495-528. 10.1146/annurev.pharmtox.45.120403.095825.CrossRefPubMed
21.
Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006, 6 (1): 38-51. 10.1038/nrc1779.CrossRefPubMed
22.
Walkinshaw DR, Yang XJ: Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol. 2008, 15 (5): 237-243.PubMedPubMedCentral
23.
Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, et al: Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003, 23 (28): 9418-9427.PubMed
24.
Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, et al: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA. 2003, 100 (4): 2041-2046. 10.1073/pnas.0437870100.CrossRefPubMedPubMedCentral
25.
Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, et al: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001, 413 (6857): 739-743. 10.1038/35099568.CrossRefPubMed
26.
Morrison BE, Majdzadeh N, Zhang X, Lyles A, Bassel-Duby R, Olson EN, D'Mello SR: Neuroprotection by histone deacetylase-related protein. Mol Cell Biol. 2006, 26 (9): 3550-3564. 10.1128/MCB.26.9.3550-3564.2006.CrossRefPubMedPubMedCentral
27.
Salminen A, Tapiola T, Korhonen P, Suuronen T: Neuronal apoptosis induced by histone deacetylase inhibitors. Brain Res Mol Brain Res. 1998, 61 (1-2): 203-206. 10.1016/S0169-328X(98)00210-1.CrossRefPubMed
28.
Boutillier AL, Trinh E, Loeffler JP: Constitutive repression of E2F1 transcriptional activity through HDAC proteins is essential for neuronal survival. Ann N Y Acad Sci. 2002, 973: 438-442. 10.1111/j.1749-6632.2002.tb04679.x.CrossRefPubMed
29.
Boutillier AL, Trinh E, Loeffler JP: Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J Neurochem. 2003, 84 (4): 814-828. 10.1046/j.1471-4159.2003.01581.x.CrossRefPubMed
30.
Morrison BE, Majdzadeh N, D'Mello SR: Histone deacetylases: focus on the nervous system. Cell Mol Life Sci. 2007, 64 (17): 2258-2269. 10.1007/s00018-007-7035-9.CrossRefPubMed
31.
Bangaru ML, Chen S, Woodliff J, Kansra S: Curcumin (diferuloylmethane) induces apoptosis and blocks migration of human medulloblastoma cells. Anticancer Res. 2010, 30 (2): 499-504.PubMed
32.
Elamin MH, Shinwari Z, Hendrayani SF, Al-Hindi H, Al-Shail E, Khafaga Y, Al-Kofide A, Aboussekhra A: Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol Carcinog. 2010, 49 (3): 302-314.PubMed
33.
Rajasekaran SA, Christiansen JJ, Schmid I, Oshima E, Ryazantsev S, Sakamoto K, Weinstein J, Rao NP, Rajasekaran AK: Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther. 2008, 7 (7): 2142-2151. 10.1158/1535-7163.MCT-08-0005.CrossRefPubMedPubMedCentral
34.
Hatton BA, Villavicencio EH, Tsuchiya KD, Pritchard JI, Ditzler S, Pullar B, Hansen S, Knoblaugh SE, Lee D, Eberhart CG, et al: The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res. 2008, 68 (6): 1768-1776. 10.1158/0008-5472.CAN-07-5092.CrossRefPubMed
35.
Shishodia S, Amin HM, Lai R, Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol. 2005, 70 (5): 700-713. 10.1016/j.bcp.2005.04.043.CrossRefPubMed
36.
Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, Tridandapani S, Anant S, Kuppusamy P: Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther. 2007, 6 (2): 178-184. 10.4161/cbt.6.2.3577.CrossRefPubMedPubMedCentral
37.
Weaver BA, Cleveland DW: Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell. 2005, 8 (1): 7-12. 10.1016/j.ccr.2005.06.011.CrossRefPubMed
38.
Rieder CL, Maiato H: Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell. 2004, 7 (5): 637-651. 10.1016/j.devcel.2004.09.002.CrossRefPubMed
39.
Gupta KK, Bharne SS, Rathinasamy K, Naik NR, Panda D: Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding. FEBS J. 2006, 273 (23): 5320-5332. 10.1111/j.1742-4658.2006.05525.x.CrossRefPubMed
40.
Perez EA: Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009, 8 (8): 2086-2095. 10.1158/1535-7163.MCT-09-0366.CrossRefPubMed
41.
Westermann S, Weber K: Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol. 2003, 4 (12): 938-947. 10.1038/nrm1260.CrossRefPubMed
42.
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001, 1 (3): 194-202. 10.1038/35106079.CrossRefPubMed
43.
Majdzadeh N, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR: HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol. 2008, 68 (8): 1076-1092. 10.1002/dneu.20637.CrossRefPubMedPubMedCentral
44.
Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK: Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem. 2004, 279 (49): 51163-51171. 10.1074/jbc.M409024200.CrossRefPubMed
45.
Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda M, Fujita M, Shimatsu A, Kita T, et al: The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest. 2008, 118 (3): 868-878.PubMedPubMedCentral
46.
Martin M, Kettmann R, Dequiedt F: Class IIa histone deacetylases: regulating the regulators. Oncogene. 2007, 26 (37): 5450-5467. 10.1038/sj.onc.1210613.CrossRefPubMed
47.
Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, Ferretti E, Miele E, et al: Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol. 2010, 12 (2): 132-142. 10.1038/ncb2013.CrossRefPubMed
48.
Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, et al: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009, 361 (12): 1173-1178. 10.1056/NEJMoa0902903.CrossRefPubMed
49.
Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, et al: Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009, 326 (5952): 572-574. 10.1126/science.1179386.CrossRefPubMed
50.
Strimpakos AS, Sharma RA: Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal. 2008, 10 (3): 511-545. 10.1089/ars.2007.1769.CrossRefPubMed
51.
Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, et al: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004, 10 (20): 6847-6854. 10.1158/1078-0432.CCR-04-0744.CrossRefPubMed
52.
Lee DS, Lee MK, Kim JH: Curcumin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells. Anticancer Res. 2009, 29 (12): 5039-5044.PubMed
53.
Freudlsperger C, Greten J, Schumacher U: Curcumin induces apoptosis in human neuroblastoma cells via inhibition of NFkappaB. Anticancer Res. 2008, 28 (1A): 209-214.PubMed
54.
Hussain AR, Al-Rasheed M, Manogaran PS, Al-Hussein KA, Platanias LC, Al Kuraya K, Uddin S: Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. Apoptosis. 2006, 11 (2): 245-254. 10.1007/s10495-006-3392-3.CrossRefPubMed
Metadata
Title
Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo
Authors
Seung Joon Lee
Candice Krauthauser
Victoria Maduskuie
Paul T Fawcett
James M Olson
Sigrid A Rajasekaran
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-144

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line

Research article

Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study

Research article

Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group

Research article

Growth of breast cancer recurrences assessed by consecutive MRI

Research article

Determinants of patient satisfaction in ambulatory oncology: a cross sectional study based on the OUT-PATSAT35 questionnaire

Research article

Lung cancer stage at diagnosis: Individual associations in the prospective VITamins and lifestyle (VITAL) cohort
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits